SCHEMBL316210

SCHEMBL316210

Nc1nccc(-c2ccccc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 1.00
ADORA2A P29274 2/20 1.00
AURKA O14965 1/20 1.00
PRKACA P17612 1/20 1.00
HSP90AB1 P08238 2/20 0.67
PTK2 Q05397 1/20 0.67
RAB9A P51151 3/20 0.61
NPC1 O15118 1/20 0.61
ADORA1 P30542 1/20 0.59
MAPK13 O15264 1/20 0.58
RAF1 P04049 1/20 0.58
MAPK9 P45984 1/20 0.58
MAPK12 P53778 1/20 0.58
MAPK11 Q15759 1/20 0.58
MAPK14 Q16539 1/20 0.58
HRH4 Q9H3N8 1/20 0.55
KMO O15229 1/20 0.55
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17186384 0.98 HSP90AA1 (0.96) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL12176972 0.96 HSP90AA1 (0.92) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL4202167 0.87 HSP90AA1 (0.76) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
Trifluoroacetic Acid SCHEMBL28137418 0.85 HSP90AA1 (0.72) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL28013042 0.84 HSP90AA1 (0.71) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL21164006 0.83 HSP90AA1 (0.70) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL2684649 0.83 HSP90AA1 (0.70) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL712182 0.82 HSP90AA1 (0.69) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
Morpholine SCHEMBL28118737 0.82 HSP90AA1 (0.68) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1
SCHEMBL4708076 0.80 HSP90AA1 (0.67) HSP90AA1ADORA2AAURKAPRKACAHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 698 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112898208-B Phenylpyrimidine amine antitumor compound and preparation method and application thereof 中国医科大学 2023-06-20 CN claimed
CN-112898208-A Phenyl pyrimidinamine antitumor compound and preparation method and application thereof 中国医科大学 2021-06-04 CN claimed
US-10988461-B2 Small molecule IRE1-α inhibitors CORNELL UNIVERSITY (US) 2021-04-27 US claimed
EP-2949647-B1 DEUTERATED PHENYL AMINO PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) 2020-08-05 EP claimed
WO-2019134082-A1 NOVEL PYRIMIDINE DERIVATIVES AS MTH1 INHIBITORS WUXI ADVANT BIOTECHNOLOGY CO., LTD. (CN) 2019-07-11 WO claimed
CN-109651366-A The preparation method of nitrogen-containing heterocycle hexafluoro borate 河南师范大学 2019-04-19 CN claimed
US-20190016706-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS CORNELL UNIVERSITY 2019-01-17 US claimed
EP-3389633-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE Natco Pharma Limited (IN) 2018-10-24 EP claimed
CN-108495620-A Pharmaceutical compositions comprising phenylaminopyrimidine derivatives 纳科制药有限公司 2018-09-04 CN claimed
CN-105399685-B The alternatively preparation method and applications of the heteroaromatic compounds of property JAK3 and/or JAK1 kinase inhibitors 深圳微芯生物科技有限责任公司 2018-05-22 CN claimed
CN-103965114-B Deuterated phenyl amino pyrimidine compounds and comprise the pharmaceutical composition of this compound SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2016-01-06 CN claimed
EP-2949647-A1 DEUTERATED PHENYL AMINO PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Suzhou Zelgen Biopharmaceuticals Co. Ltd. (CN) 2015-12-02 EP claimed
CN-104955811-A Deuterated phenylaminopyrimidine compounds and pharmaceutical compositions containing same SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD 2015-09-30 CN claimed
CN-104447706-A 4-phenyl-2-aminopyrimidine compound, as well as preparation method and applications thereof UNIV SHANDONG 2015-03-25 CN claimed
CN-103965114-A Deuterated phenylamino pyrimidine compound and drug composition containing the same SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD 2014-08-06 CN claimed
CN-103044394-A Phenyl aminopyrimidine derivant and preparation method and application thereof BEIJING INST TECHNOLOGY 2013-04-17 CN claimed
CN-101068805-A Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase NATCO PHARMA LTD (IN) 2007-11-07 CN claimed
EP-1597398-A1 TAILORED TREATMENT SUITABLE FOR DIFFERENT FORMS OF MASTOCYTOSIS AB Science (FR) 2005-11-23 EP claimed
WO-2004098612-A2 CALCITRIOL ANALOGS OF USES THEREOF AB SCIENCE (FR) 2004-11-18 WO claimed
WO-2004076693-A1 TAILORED TREATMENT SUITABLE FOR DIFFERENT FORMS OF MASTOCYTOSIS AB SCIENCE (FR) 2004-09-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016706-A1 SMALL MOLECULE IRE1-ALPHA INHIBITORS XBP1, ERN1, ERN2 HSP90AA1 129/4885ADORA2A 4636/4885AURKA 3183/4885
US-10988461-B2 Small molecule IRE1-α inhibitors XBP1, ERN1, ERN2 HSP90AA1 118/4885ADORA2A 4557/4885AURKA 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.